These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 26522769

  • 1. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R, Hirai I, Sasaki T, Ono K, Ramasoota P, Ikuta K, Kurosu T.
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
    Wang M, Yang F, Huang D, Huang Y, Zhang X, Wang C, Zhang S, Zhang R.
    Front Cell Infect Microbiol; 2017 Dec; 7():157. PubMed ID: 28536674
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S, Chan KW, Wang J, Rivino L, Lok SM, Vasudevan SG.
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
    Fink AL, Williams KL, Harris E, Alvine TD, Henderson T, Schiltz J, Nilles ML, Bradley DS.
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM.
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
    Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.
    Cell Host Microbe; 2010 Sep 16; 8(3):271-83. PubMed ID: 20833378
    [Abstract] [Full Text] [Related]

  • 19. Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
    Mady BJ, Kurane I, Erbe DV, Fanger MW, Ennis FA.
    J Gen Virol; 1993 May 16; 74 ( Pt 5)():839-44. PubMed ID: 8492089
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.